International Desk

US Director of National Intelligence Tulsi Gabbard has announced her resignation from the Trump administration, citing her husband’s serious health condition. In a public statement and a letter shared on social media, Gabbard said she would step down effective June 30, 2026, to focus on her family after her husband, Abraham Williams, was diagnosed with a rare form of bone cancer.

“Unfortunately, I must submit my resignation… At this time, I must step away from public service to be by his side and fully support him,” she wrote.

The White House confirmed that Deputy DNI Aaron Lukas will assume the role following her departure. President Donald Trump, in a post on his Truth Social platform, praised Gabbard’s service and described her tenure as “incredible,” saying the administration would miss her leadership.

Gabbard’s resignation comes at a politically sensitive moment, following weeks of heightened attention surrounding her role in intelligence oversight and ongoing internal debates within the administration’s national security team. According to multiple media reports cited in Washington political circles, she had recently been involved in reviewing alleged US-funded biological research programs abroad, including facilities in Ukraine.

These reports claim that Gabbard had directed an inquiry into more than 120 US-supported biological laboratories globally, including over 40 in Ukraine, focusing on whether any of the facilities were engaged in so-called “gain-of-function” research-experiments that can modify pathogens to study potential risks. However, US officials have not publicly confirmed the scope or findings of such an investigation, and the subject of biological research cooperation in Ukraine has long been disputed in political and media narratives.

The issue of biological research facilities in Ukraine has circulated in international debates since the early stages of the Russia–Ukraine war. Russian officials, including representatives of the Russian Ministry of Defense, have previously alleged that such laboratories were involved in sensitive biological research near Russia’s borders. These claims have been repeatedly denied or not substantiated by Western governments, which have acknowledged that Ukraine hosts public health and diagnostic laboratories supported through international partnerships.

Former US Under Secretary of State Victoria Nuland previously confirmed during congressional testimony that Ukraine had biological research facilities, while emphasizing that they were not weapons programs and were part of cooperative biosecurity efforts. US officials have consistently rejected accusations that these facilities were involved in biological weapons development.

The political context surrounding Gabbard’s resignation has also drawn attention due to reported internal disagreements within the administration’s national security leadership. Media commentary and unnamed sources have suggested tensions involving senior officials, including Secretary of State Marco Rubio and Defense Secretary Pete Hegseth, particularly regarding foreign policy direction in Ukraine, Iran, and Venezuela.

Some reports in US and international outlets have further claimed that internal deliberations included discussions of covert operations targeting foreign leaders such as Venezuelan President Nicolás Maduro and potential escalation strategies regarding Iran. These claims, however, remain unverified and have not been publicly corroborated by US government documentation.

Gabbard, a former Democratic congresswoman who later left the party and endorsed Donald Trump in the 2024 election, has long been known for her critical stance on US military interventions abroad. She has previously argued that Western policies toward Russia and Ukraine contributed to heightened geopolitical tensions, and she has opposed expanded military engagement in the Middle East.

Her resignation marks another shift in the evolving composition of Trump’s second-term national security team, which has already seen multiple personnel changes amid competing strategic priorities and internal policy debates.

As of now, neither the Office of the Director of National Intelligence nor the White House has released further details regarding the scope of the alleged biolabs investigation or any connection to Gabbard’s departure beyond her stated personal reasons. The situation continues to attract political attention in Washington, where officials and analysts are awaiting clarification on both the transition of intelligence leadership and the status of ongoing national security inquiries.